 |
BioWorld-International-2004-03-24
Researchers Find 'P-Loop' To Be Implicated In Cancer
Atugen Raises EUR5M As Fuel For SiRNA Drug Development
Following a change in strategy made public last month, Atugen AG secured €5 million in the first closing of its third round of financing. The company intends to use the new capital to accelerate its work on small interfering RNA therapeutics. (BioWorld International)